Global control of tuberculosis: From extensively drug-resistant to untreatable tuberculosis

The Lancet Respiratory Medicine

Volumn 2, Issue 4, 2014, Pages 321-338

  Dheda, Keertan ^a   Gumbo, Tawanda ^b   Gandhi, Neel R ^c   Murray, Megan ^d   Theron, Grant ^a   Udwadia, Zarir ^e   Migliori, G B ^f   Warren, Robin ^g  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f IRCCS   (Italy)

^g UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CILASTATIN PLUS IMIPENEM; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE;

BACTERIAL STRAIN; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE TRANSMISSION; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTREMELY DRUG RESISTANT TUBERCULOSIS; GENOTYPE; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION PREVENTION; LUNG RESECTION; MEDICOLEGAL ASPECT; MOLECULAR EPIDEMIOLOGY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MUTANT; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TOTALLY DRUG RESISTANT TUBERCULOSIS; TUBERCULOSIS CONTROL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HEALTH; PATHOGENICITY; PREVENTION AND CONTROL; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GLOBAL HEALTH; HUMANS; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84897963303     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70031-1     Document Type: Review

References (176)

1. Global Tuberculosis Report 2012 2012, WHO, World Health Organization, Geneva.
2. The new WHO report on anti-tuberculosis drug resistance-multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2011, WHO, World Health Organization, Geneva.
3. Klopper M, Warren RM, Hayes C, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013, 19:449-455.
4. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
5. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
6. Pooran A, Pieterson E, Davids M, Theron G, Dheda K What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?. PLoS One 2013, 8:e54587.
7. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007, 12:E070517.1.
8. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283:2537-2545.
9. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
10. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010, 182:113-119.
11. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 2002, 6:858-864.
12. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009, 9:153-161.
13. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012, 39:1425-1431.
14. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012, 90:111-119D.
15. Akcakir Y Correlates of treatment outcomes of multidrug-resistant tuberculosis (MDR-TB): a systematic review and meta-analysis 2010, McGill University, Montreal, QC.
16. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010, 375:1798-1807.
17. Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr 2011, 57:146-152.
18. O'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013, 19:416-424.
19. Symons G, Shean K, Pietersen E, et al. A historical review of XDR tuberculosis in the Western Cape province of South Africa. S Afr Med J 2011, 101:636-638.
20. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008, 12:1182-1189.
21. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur Respir J 2013, 42:169-179.
22. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006, 55:301-305. Centers for Disease Control and Prevention.
23. Holtz TH XDR-TB in South Africa: revised definition. PLoS Med 2007, 4:e161.
24. Holtz TH, Cegielski JP Origin of the term XDR-TB. Eur Respir J 2007, 30:396.
25. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007, 30:623-626. the SMIRA/TBNET Study Group.
26. Treatment of tuberculosis: guidelines 2009, WHO, Stop TB InitiativeStop TB Initiative, World Health Organization, Geneva. 4th edn.
27. Mathema B, Kurepina N, Fallows D, Kreiswirth BN Lessons from molecular epidemiology and comparative genomics. Semin Respir Crit Care Med 2008, 29:467-480.
28. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997, 35:907-914.
29. van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993, 31:406-409.
30. Allix C, Supply P, Fauville-Dufaux M Utility of fast mycobacterial interspersed repetitive unit-variable number tandem repeat genotyping in clinical mycobacteriological analysis. Clin Infect Dis 2004, 39:783-789.
31. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994, 330:1703-1709.
32. Van Rie A, Warren R, Richardson M, et al. Classification of drug-resistant tuberculosis in an epidemic area. Lancet 2000, 356:22-25.
33. Andrews JR, Gandhi NR, Moodley P, et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 2008, 198:1582-1589. the Tugela Ferry Care and Research Collaboration.
34. Bifani PJ, Mathema B, Liu Z, et al. Identification of a W variant outbreak of Mycobacterium tuberculosis via population-based molecular epidemiology. JAMA 1999, 282:2321-2327.
35. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010, 16:264-271.
36. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
37. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011, 53:369-372.
38. van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005, 172:636-642.
39. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. PLoS One 2010, 5:e15735.
40. Balaji V, Daley P, Anand AA, et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010, 5:e9527.
41. Faustini A, Hall AJ, Perucci CA Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006, 61:158-163.
42. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013, 91:36-45.
43. Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012, 366:2161-2170.
44. Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res 2012, 40:436-445.
45. Ricks PM, Mavhunga F, Modi S, et al. Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infect Dis 2012, 12:385.
46. Nodieva A, Jansone I, Broka L, Pole I, Skenders G, Baumanis V Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010, 14:427-433.
47. Wang W, Hu Y, Mathema B, Jiang W, Kreiswirth B, Xu B Recent transmission of W-Beijing family Mycobacterium tuberculosis in rural eastern China. Int J Tuberc Lung Dis 2012, 16:306-311.
48. Li X, Zhang Y, Shen X, et al. Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis 2007, 195:864-869.
49. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417. the Global PETTS Investigators.
50. Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008, 46:42-49.
51. Blower SM, Chou T Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004, 10:1111-1116.
52. Cohen T, Murray M Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004, 10:1117-1121.
53. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
54. Uys PW, Warren R, van Helden PD, Murray M, Victor TC Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where Mycobacterium tuberculosis infections are highly prevalent. J Clin Microbiol 2009, 47:1484-1490.
55. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 2008, 105:11293-11298.
56. Lin HH, Dowdy D, Dye C, Murray M, Cohen T The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ 2012, 90:739. 47A.
57. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012, 9:e1001347.
58. Luria SE, Delbrück M Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28:491-511.
59. David HL Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970, 20:810-814.
60. Desouza GA, Fortuin S, Aguilar D, et al. Using a label-free proteomic method to identify differentially abundant proteins in closely related hypo- and hyper-virulent clinical Mycobacterium tuberculosis Beijing isolates. Mol Cell Proteomics 2010, 9:2414-2423.
61. Velayati AA, Farnia P, Ibrahim TA, et al. Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy. Chemotherapy 2009, 55:303-307.
62. Velayati AA, Farnia P, Masjedi MR, et al. Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. Eur Respir J 2009, 34:1202-1203.
63. Mitchison DA How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998, 2:10-15.
64. Gumbo T, Louie A, Deziel MR, Drusano GL Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005, 49:3178-3181.
65. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004, 190:1642-1651.
66. Gumbo T, Dona CS, Meek C, Leff R Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009, 53:3197-3204.
67. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007, 51:3781-3788.
68. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007, 195:194-201.
69. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007, 51:2329-2336.
70. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010, 201:1225-1231.
71. Pasipanodya JG, Gumbo T A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol 2011, 11:457-463.
72. Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012, 56:4806-4815.
73. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011, 184:269-276.
74. Machado D, Couto I, Perdigão J, et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 2012, 7:e34538.
75. Chatterjee A, Saranath D, Bhatter P, Mistry N Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 2013, 8:e54717.
76. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011, 204:1951-1959.
77. de Steenwinkel JE, ten Kate MT, de Knegt GJ, et al. Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012, 56:4937-4944.
78. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011, 55:4122-4127.
79. Pasipanodya JG, Srivastava S, Gumbo T Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012, 55:169-177.
80. Pasipanodya JG, Gumbo T A meta-analysis of self-administered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013, 57:21-31.
81. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013, 208:1464-1473.
82. Vadwai V, Daver G, Udwadia Z, Sadani M, Shetty A, Rodrigues C Clonal population of Mycobacterium tuberculosis strains reside within multiple lung cavities. PLoS One 2011, 6:e24770.
83. Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 2013, 57:2613-2619.
84. Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013, 45:784-790.
85. Borrell S, Gagneux S Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1456-1466.
86. Gumbo T Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet 2013, 45:720-721.
87. Comas I, Borrell S, Roetzer A, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012, 44:106-110.
88. Sun G, Luo T, Yang C, et al. Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis 2012, 206:1724-1733.
89. Basile JI, Geffner LJ, Romero MM, et al. Outbreaks of Mycobacterium tuberculosis MDR strains induce high IL-17 T-cell response in patients with MDR tuberculosis that is closely associated with high antigen load. J Infect Dis 2011, 204:1054-1064.
90. Eum SY, Lee YJ, Min JH, et al. Association of antigen-stimulated release of tumor necrosis factor-alpha in whole blood with response to chemotherapy in patients with pulmonary multidrug-resistant tuberculosis. Respiration 2010, 80:275-284.
91. Geffner L, Yokobori N, Basile J, et al. Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains. Infect Immun 2009, 77:5025-5034.
92. Semple PL, Binder AB, Davids M, Maredza A, van Zyl-Smit RN, Dheda K Regulatory T-cells attenuate mycobacterial stasis in alveolar and blood-derived macrophages from patients with TB. Am J Respir Crit Care Med 2013, 187:1249-1258.
93. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2:108-122.
94. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013, 138:105-115.
95. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y The immunology of tuberculosis: from bench to bedside. Respirology 2010, 15:433-450.
96. Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007, 370:1500-1507.
97. Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 2009, 106:7672-7677.
98. Jones-López EC, Namugga O, Mumbowa F, et al. Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study. Am J Respir Crit Care Med 2013, 187:1007-1015.
99. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM Superspreading and the effect of individual variation on disease emergence. Nature 2005, 438:355-359.
100. Woolhouse ME, Dye C, Etard JF, et al. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. Proc Natl Acad Sci USA 1997, 94:338-342.
101. Jones-López EC, Namugga O, Mumbowa F, et al. Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study. Am J Respir Crit Care Med 2013, 187:1007-1015.
102. Andersson DI The biological cost of mutational antibiotic resistance: any practical conclusions?. Curr Opin Microbiol 2006, 9:461-465.
103. Müller B, Borrell S, Rose G, Gagneux S The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013, 29:160-169.
104. Borrell S, Gagneux S Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2011, 17:815-820.
105. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010, 363:1005-1015.
106. Steingart KR Xpert MTB/RIF test for detection of pulmonary tuberculosis and rifampicin resistance. J Evid Based Med 2013, 6:58.
107. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 2014, 383:424-435. for the TB-NEAT team.
108. Jacobson KR, Theron D, Kendall EA, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013, 56:503-508.
109. Rishi S, Sinha P, Malhotra B, Pal N A comparative study for the detection of mycobacteria by BACTEC MGIT 960, Lowenstein Jensen media and direct AFB smear examination. Indian J Med Microbiol 2007, 25:383-386.
110. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 2012, 16:203-205.
111. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011 2011, WHO, World Health Organization, Geneva.
112. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008, 177:787-792.
113. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 2012, 50:3712-3716.
114. Rutledge JA, Crouch JB The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium. Am Rev Tuberc 1919, 2:755-763.
115. Hillemann D, Rüsch-Gerdes S, Richter E Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009, 47:1767-1772.
116. Barnard M, Warren R, Gey van Pittius N, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med 2012, 186:1298-1305.
117. Miotto P, Cabibbe AM, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012, 40:690-698.
118. Dixit P, Singh U, Sharma P, Jain A Evaluation of nitrate reduction assay, resazurin microtiter assay and microscopic observation drug susceptibility assay for first line antitubercular drug susceptibility testing of clinical isolates of M tuberculosis. J Microbiol Methods 2012, 88:122-126.
119. Dheda K, Warren RM, Zumla A, Grobusch MP Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010, 24:705-725.
120. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
121. Migliori GB, Dheda K, Centis R, et al. Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health 2010, 15:1052-1066.
122. WHO updated references on management of drug-resistant tuberculosis: guidelines for the programmatic management of drug-resistant tuberculosis-2011 update 2011, WHO, World Health Organization, Geneva.
123. Schaaf HS, Moll AP, Dheda K Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Clin Chest Med 2009, 30:667-683. vii-viii.
124. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014, published online Jan 17. http://dx.doi.org/10.1016/S0140-6736(13)62675-6.
125. Müller B, Streicher EM, Hoek KG, et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?. Int J Tuberc Lung Dis 2011, 15:344-351.
126. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51:6-14.
127. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013, 41:1386-1392.
128. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One 2013, 8:e59414.
129. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.
130. Voelker R MDR-TB has new drug foe after fast-track approval. JAMA 2013, 309:430.
131. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
132. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
133. O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis 2009, 13:855-861.
134. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181:80-86. the Tugela Ferry Care and Research (TF CARES) Collaboration.
135. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013, 8:e63057.
136. Dubrovina I, Miskinis K, Lyepshina S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics?. Int J Tuberc Lung Dis 2008, 12:756-762.
137. Nelson LJ, Talbot EA, Mwasekaga MJ, et al. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005, 366:488-490.
138. Nunes EA, De Capitani EM, Coelho E, et al. Patterns of anti-tuberculosis drug resistance among HIV-infected patients in Maputo, Mozambique, 2002-2003. Int J Tuberc Lung Dis 2005, 9:494-500.
139. Wallengren K, Scano F, Nunn P, et al. Drug-resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. Emerg Infect Dis 2011, 17:1913-1916.
140. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008, 372:1403-1409.
141. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003, 348:119-128.
142. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008, 359:563-574.
143. Abdool-Karim SS, Abdool-Karim Q, Friedland G, Lalloo U, El-Sadr WM Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004, 18:975-979. the START project.
144. Dartois V, Barry CE Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010, 5:96-114.
145. Brust JC, Shah NS, van der Merwe TL, et al. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr 2013, 62:436-440.
146. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One 2012, 7:e40781.
147. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 2009, 4:e7186.
148. Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006, 144:650-659.
149. Skolimowska KH, Rangaka MX, Meintjes G, et al. Altered ratio of IFN-γ/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV-tuberculosis immune reconstitution inflammatory syndrome. PLoS One 2012, 7:e46481.
150. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
151. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
152. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
153. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481. the CAMELIA (ANRS 1295-CIPRA KH001) Study Team.
154. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491. the AIDS Clinical Trials Group Study A5221.
155. Gandhi NR, Moll AP, Lalloo U, et al. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study. J Acquir Immune Defic Syndr 2009, 50:37-43. the Tugela Ferry Care and Research (TFCaRes) Collaboration.
156. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 43:42-46.
157. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009, 50:148-152. the COMESEM Cohort.
158. Dheda K, Lampe FC, Johnson MA, Lipman MC Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004, 190:1670-1676.
159. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008, 300:2153-2160.
160. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009, 33:871-881.
161. Chaulk CP, Kazandjian VA Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998, 279:943-948.
162. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012, 9:e1001300. the Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB.
163. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013, 42:156-168.
164. Agonafir M, Lemma E, Wolde-Meskel D, et al. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. Int J Tuberc Lung Dis 2010, 14:1259-1265.
165. Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012, 16:90-97.
166. Brust JC, Shah NS, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis 2012, 16:998-1004.
167. Heller T, Lessells RJ, Wallrauch CG, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010, 14:420-426.
168. Ajbani K, Rodrigues C, Shenai S, Mehta A Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011, 49:1588-1590.
169. Dheda K, Migliori GB The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 2012, 379:773-775.
170. Denholm JT, Amon JJ, O'Brien R, et al. Attitudes towards involuntary incarceration for tuberculosis: a survey of Union members. Int J Tuberc Lung Dis 2014, 18:155-159.
171. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F Tuberculosis among health care workers. Emerg Infect Dis 2011, 17:488-494.
172. O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010, 153:516-522.
173. Jarand J, Shean K, O'Donnell M, et al. Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010, 15:1179-1184.
174. The Joint WHO-ILO-UNAIDS policy guidelines on improving health workers' access to HIV and TB prevention, treatment, care and support services 2010, WHO, International Labour OrganizationInternational Labour Organization, World Health Organization, Geneva.
175. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011, 377:147-152.
176. Vella V, Racalbuto V, Guerra R, et al. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2011, 15:1170-1175. i.